Revolution Medicines, Inc. Financing Cash Flow
Revolution Medicines, Inc. (RVMD) reported Financing Cash Flow of $2.66 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- Revolution Medicines, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.42B, a 843.35% increase year-over-year.
- Revolution Medicines, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $238.74M, a 27216.25% increase year-over-year.
- Revolution Medicines, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $365.66M, a 58.15% decline year-over-year.
- Revolution Medicines, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$1.59M, a 102.06% decline year-over-year.
- Revolution Medicines, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $621.52M, a 35.22% decline from fiscal 2024.
- Revolution Medicines, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $959.41M, a 21.95% decline from fiscal 2023.
- Revolution Medicines, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $1.23B, a 307.79% increase from fiscal 2022.
- Revolution Medicines, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $301.43M, a 2.47% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.42B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.66B 10-Q · filed 2026-08-05 | $3.02B derived: sum of 3 quarters · filed 2026-08-05 | $3.02B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $238.74M 10-Q · filed 2026-05-06 | $604.40M derived: sum of 2 quarters · filed 2026-05-06 | $602.81M derived: sum of 3 quarters · filed 2026-05-06 | $859.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $365.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $364.07M derived: sum of 2 quarters · filed 2026-02-25 | $620.65M derived: sum of 3 quarters · filed 2026-08-05 | $621.52M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $254.99M derived: sum of 2 quarters · filed 2026-08-05 | $255.87M 10-Q · filed 2025-11-05 | $1.13B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $256.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $257.46M 10-Q · filed 2026-08-05 | $1.13B derived: sum of 3 quarters · filed 2026-08-05 | $1.21B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $874.00K 10-Q · filed 2026-05-06 | $874.68M derived: sum of 2 quarters · filed 2026-05-06 | $951.97M derived: sum of 3 quarters · filed 2026-05-06 | $959.48M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $873.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $951.10M derived: sum of 2 quarters · filed 2026-02-25 | $958.60M derived: sum of 3 quarters · filed 2026-02-25 | $959.41M 10-K · filed 2026-02-25 |
| 2024-09-30 | $77.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $84.80M derived: sum of 2 quarters · filed 2025-11-05 | $85.61M 10-Q · filed 2025-11-05 | $924.96M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $8.31M 10-Q · filed 2025-08-06 | $847.67M derived: sum of 3 quarters · filed 2026-02-25 | $848.68M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $810.00K 10-Q · filed 2025-05-07 | $840.16M derived: sum of 2 quarters · filed 2026-02-25 | $841.17M derived: sum of 3 quarters · filed 2026-02-25 | $905.80M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $839.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $840.37M derived: sum of 2 quarters · filed 2026-02-25 | $905.00M derived: sum of 3 quarters · filed 2026-02-25 | $1.23B 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $65.64M derived: sum of 2 quarters · filed 2024-11-06 | $389.85M 10-Q · filed 2024-11-06 | $441.21M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $64.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $388.83M 10-Q · filed 2024-08-07 | $440.20M derived: sum of 3 quarters · filed 2025-02-26 | $688.53M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $324.20M 10-Q · filed 2024-05-08 | $375.57M derived: sum of 2 quarters · filed 2025-02-26 | $623.90M derived: sum of 3 quarters · filed 2025-02-26 | $625.33M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $51.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $299.70M derived: sum of 2 quarters · filed 2025-02-26 | $301.13M derived: sum of 3 quarters · filed 2025-02-26 | $301.43M 10-K · filed 2025-02-26 |
| 2022-09-30 | $248.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $249.76M derived: sum of 2 quarters · filed 2023-11-06 | $250.07M 10-Q · filed 2023-11-06 | $260.80M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.73M 10-Q · filed 2023-08-08 | $12.46M derived: sum of 3 quarters · filed 2024-02-26 | $12.78M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $305.00K 10-Q · filed 2023-05-08 | $11.03M derived: sum of 2 quarters · filed 2024-02-26 | $11.35M derived: sum of 3 quarters · filed 2024-02-26 | $12.22M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $10.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $11.05M derived: sum of 2 quarters · filed 2024-02-26 | $11.91M derived: sum of 3 quarters · filed 2024-02-26 | $294.18M 10-K · filed 2024-02-26 |
| 2021-09-30 | $319.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.19M derived: sum of 2 quarters · filed 2022-11-07 | $283.45M 10-Q · filed 2022-11-07 | $284.94M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $868.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $283.13M 10-Q · filed 2022-08-09 | $284.62M derived: sum of 3 quarters · filed 2023-02-27 | $453.50M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $282.26M 10-Q · filed 2022-05-09 | $283.75M derived: sum of 2 quarters · filed 2023-02-27 | $452.63M derived: sum of 3 quarters · filed 2023-02-27 | $451.30M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $170.37M derived: sum of 2 quarters · filed 2023-02-27 | $169.03M derived: sum of 3 quarters · filed 2023-02-27 | $422.78M 10-K · filed 2023-02-27 |
| 2020-09-30 | $168.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $167.55M derived: sum of 2 quarters · filed 2021-11-10 | $421.29M 10-Q · filed 2021-11-10 | $419.76M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $252.41M 10-Q · filed 2021-08-11 | $250.87M derived: sum of 3 quarters · filed 2022-02-28 | $260.88M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $253.74M 10-Q · filed 2021-05-10 | $252.21M derived: sum of 2 quarters · filed 2022-02-28 | $262.21M derived: sum of 3 quarters · filed 2022-02-28 | $352.39M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $8.47M derived: sum of 2 quarters · filed 2022-02-28 | $98.64M derived: sum of 3 quarters · filed 2022-02-28 | $98.66M 10-K · filed 2022-02-28 |
| 2019-09-30 | $10.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $100.18M derived: sum of 2 quarters · filed 2020-11-12 | $100.19M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $90.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $90.19M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $14.00K 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $60.85M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |